RSV viral infections are a leading cause of hospitalization for infants and one of the causes of child mortality worldwide. Recently, the U.S. Food and Drug Administration (FDA) approved the drug nirsevimab, a monoclonal antibody that can protect young children from RSV infection throughout the season. In Thailand, the Food and Drug Administration has also approved this medication.
Nirsevimab, or "Beyfortus," requires only a single injection to reduce the risk of severe infection by up to 74.5%, unlike Synagis, which requires multiple injections and is costly. This drug provides immediate protection during the time when children are at high risk. Therefore, using nirsevimab is crucial in reducing the risk from RSV and preventing children from needing hospitalization. Additionally, there is a demand for an RSV vaccine for children in the future to create long-term immunity effectively.
This represents a significant step forward in preventing RSV virus infections in young children, which will help lower hospitalization rates and severe health issues. Having effective preventive measures will enhance children's health in the future and reduce the overall burden on the healthcare system.
For more information: CIMJournal website
E-mail: hwplus.editor@gmail.com
Link: https://cimjournal.com/
EN
CN
DE
JP
TH
